Real-world outcomes with novel therapies in R/R DLBCL.
Increased Real-World Biomarker Test Utilization in Patients with Early-Stage Non-Small Cell Lung Cancer in the United States, 2011 to 2021
Abstract 967: Real-world transcriptomic biomarkers as replacement for immunohistochemistry and FISH studies in breast cancer
Real-World Study of First-Line Treatment Patterns in HR+/HER2- Metastatic Breast Cancer (MBC) at a Tertiary Care Cancer Institute
Real-World Study of Disease-Free Survival and Associated Patient Characteristics in Early-Stage Non–Small Cell Lung Cancer (NSCLC): A Retrospective Observational Study
Continuous maintenance (Maint) capecitabine (Cape) dosing for colorectal (CRC) and pancreatic cancers (PC): A single-institution, retrospective, real-world study
Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data
Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)
Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy
Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study
